NCT06103864 2026-03-31A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerAstraZenecaPhase 3 Recruiting625 enrolled
NCT04900818 2026-03-05Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsI-Mab Biopharma US LimitedPhase 1 Recruiting330 enrolled
NCT02671435 2025-07-22A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsMedImmune LLCPhase 1/2 Active not recruiting383 enrolled 48 charts
NCT03238027 2024-05-17A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid TumorsSyndax PharmaceuticalsPhase 1 Completed45 enrolled
NCT03162224 2022-08-25Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerMedImmune LLCPhase 1/2 Completed35 enrolled 25 charts
NCT02805660 2021-04-06Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLCMirati Therapeutics Inc.Phase 1/2 Terminated83 enrolled 26 charts
NCT02572687 2021-01-20A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesEli Lilly and CompanyPhase 1 Completed85 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled
NCT02027961 2019-05-17Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneMedImmune LLCPhase 1 Completed68 enrolled